veliparib

Drug Overview

Veliparib is a type of “Smart Drug” designed to fight cancer by blocking how cancer cells fix their own damaged DNA. It belongs to a modern group of medicines called Targeted Therapy. While traditional chemotherapy attacks all fast-growing cells, targeted therapies are built to find and exploit specific weaknesses inside cancer cells, leaving more healthy cells alone.

• Generic Name: Veliparib (also known in research as ABT-888)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Poly (ADP-ribose) Polymerase (PARP) Inhibitor
• Route of Administration: Oral (Capsules taken by mouth)
• FDA Approval Status: Investigational. Veliparib has been studied extensively in late-stage clinical trials but is not currently FDA-approved for general public use.

What Is It and How Does It Work? (Mechanism of Action)

Veliparib is a Targeted Therapy that attacks a cancer cell’s “repair kits.” Every time a cell divides, its DNA can get slightly damaged. Cells use these repair kits to fix the damage so they can survive.

The First Repair Kit: PARP Enzymes

Inside our cells, an enzyme called PARP acts like a tiny mechanic. Its main job is to fix small, single-strand breaks in the DNA. Veliparib works by binding directly to the PARP enzymes (specifically PARP1 and PARP2), blocking them from doing their job. It also “traps” the PARP enzyme on the DNA, creating a toxic roadblock when the cell tries to copy its DNA to divide.

The Second Repair Kit: BRCA Genes

When PARP is blocked, the small DNA breaks turn into severe, double-strand breaks. Normal, healthy cells can survive this because they have a backup repair kit controlled by genes like BRCA1 and BRCA2.

The Fatal Blow: Synthetic Lethality

Many ovarian and breast cancer cells have mutated (broken) BRCA genes. Because their backup repair kit is already broken, adding veliparib takes away their primary repair kit. This “double-hit” causes massive DNA damage, and the cancer cell simply self-destructs. In the medical field, this powerful concept is called synthetic lethality.

FDA-Approved Clinical Indications

Because veliparib is an investigational drug, it does not currently have standard FDA-approved uses. It has primarily been given to patients participating in clinical trials.

• Oncological Uses (Investigational):
  • Ovarian Cancer: Advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
  • Breast Cancer: HER2-negative metastatic or advanced breast cancer in patients with BRCA1 or BRCA2 genetic mutations.
  • Non-Small Cell Lung Cancer (NSCLC): Studied in combination with chemotherapy.
• Non-oncological Uses:
  • There are no non-cancer uses for this medication.

Dosage and Administration Protocols

Because veliparib is experimental, dosages depend strictly on the specific clinical trial protocol. It is taken as a pill, making it a convenient option compared to hospital IV drips.

Dose Adjustments:

• Renal (Kidney) Insufficiency: Veliparib is cleared from the body by the kidneys. If blood tests show that a patient’s kidneys are struggling, the doctor will lower the dose or pause the medication to prevent it from building up to unsafe levels.
• Hepatic (Liver) Insufficiency: Mild liver issues typically do not require dose changes, but severe liver impairment requires close monitoring.

Clinical Efficacy and Research Results

Extensive clinical trials published between 2020 and 2024 have provided deep insights into how veliparib performs.

• Ovarian Cancer (VELIA Trial): When veliparib was added to standard chemotherapy and continued as a “maintenance” drug, it significantly delayed the cancer from growing. For patients with BRCA mutations, the cancer was held off for a median of 34.7 months compared to 22.0 months for those on a placebo.
• Breast Cancer (BROCADE3 Trial): In patients with BRCA-mutated advanced breast cancer, adding veliparib to chemotherapy improved Progression-Free Survival (PFS), delaying cancer growth for a median of 14.5 months versus 12.6 months for placebo.
• Current Status: Despite these positive numbers, veliparib did not show a large enough improvement in Overall Survival (OS) to easily beat other PARP inhibitors already available on the market. As a result, its development for some of these cancers has been paused by the manufacturer.

Safety Profile and Side Effects

Like all PARP inhibitors, veliparib can affect healthy cells that multiply quickly, particularly in the bone marrow and the digestive system.

Important Safety Note: Because veliparib is investigational, it does not have an official “Black Box Warning.” However, all PARP inhibitors carry strict class warnings for rare but fatal bone marrow cancers, such as Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML).

Common Side Effects (>10%)

• Nausea and Vomiting: Very common, especially at higher doses.
• Fatigue: Feeling extremely tired or lacking physical energy.
• Anemia: Low red blood cell count, causing weakness.
• Neutropenia: Low white blood cell count, leading to a higher risk of getting sick.
• Thrombocytopenia: Low platelets, which can cause easy bruising or bleeding.

Serious Adverse Events

• Severe Bone Marrow Suppression: Dangerously low blood counts that may require blood transfusions.
• Seizures: Extremely rare, but noted in early Phase 1 trials when given at very high doses.
• Secondary Blood Cancers (MDS/AML): A very small percentage of patients taking PARP inhibitors develop secondary blood cancers over time.

Management Strategies

• Blood Monitoring: Patients must have a Complete Blood Count (CBC) drawn every week during the first few months to catch dropping blood levels early.
• Anti-Nausea Medication: Doctors often prescribe medicines (like ondansetron) to be taken before veliparib to prevent an upset stomach.

Research Areas

In the fields of Immunotherapy and cancer biology, scientists are studying how PARP inhibitors like veliparib alter the environment around a tumor. When veliparib damages a cancer cell’s DNA, the dying cell releases fragments that can act like a “flare gun,” alerting the body’s immune system. Researchers are actively testing whether combining veliparib with immune checkpoint inhibitors can help regenerate a strong, natural immune response against stubborn solid tumors.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Genetic Testing: A blood or saliva test to check for BRCA1 and BRCA2 mutations. This tells the doctor if your specific cancer is likely to respond to the drug.
• Complete Blood Count (CBC): To ensure your bone marrow is healthy enough to start treatment.
• Kidney Function Test: To make sure your kidneys can safely filter the drug.

Precautions During Treatment

• Pregnancy Warning: This drug targets DNA and can cause severe birth defects. Highly effective birth control must be used during treatment and for several months after stopping.
• Infection Risks: Because the drug lowers your white blood cells, you must wash your hands frequently and avoid large, enclosed crowds.

“Do’s and Don’ts” list

• DO take the capsules at the exact same time every day to keep the medicine levels steady in your body.
• DO report any sudden fever over 100.4°F (38°C) to your oncology team immediately. This is a medical emergency when your white blood cells are low.
• DON’T crush, chew, or open the capsules; swallow them whole with a glass of water.
• DON’T take any new vitamins, herbal supplements, or other medications without checking with your pharmacist, as they could interact with the trial drug.

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Veliparib is an investigational medication and is only available to patients participating in approved clinical trials. Always consult your oncologist or licensed healthcare provider regarding your specific medical condition, genetic testing, and treatment options. Individual results and side effects from clinical trials may vary.